Difficulty: Medium
Average Score: 87%
Practice
A 9-year-old boy develops acute myelogenous leukemia (AML) one year after completion of therapy for soft tissue sarcoma at his right thigh. Which of the following chemotherapeutic agents is MOST likely the cause of secondary acute myelogenous leukemia AML in this boy?
Correct answer
C
Rationale
In understanding why etoposide is the most likely cause of secondary acute myelogenous leukemia (AML) in the 9-year-old boy, we need to consider the drug's mechanism of action. Etoposide is a topoisomerase II inhibitor, which can lead to DNA damage and chromosomal translocations associated with the development of secondary malignancies like AML.
Regarding the other options:
A) Cyclophosphamide is alkylating agent associated with secondary malignancies but less commonly linked to AML compared to etoposide.
B) Vincristine is a microtubule inhibitor and is not typically associated with secondary AML.
D) Doxorubicin is an anthracycline that can cause secondary leukemias, but etoposide has a stronger association with AML development.
Educationally, this question highlights the importance of understanding the long-term effects of chemotherapy in pediatric oncology patients. Healthcare providers need to be aware of the potential risks associated with different chemotherapeutic agents to provide comprehensive care and long-term surveillance for these vulnerable patients.
Regarding the other options:
A) Cyclophosphamide is alkylating agent associated with secondary malignancies but less commonly linked to AML compared to etoposide.
B) Vincristine is a microtubule inhibitor and is not typically associated with secondary AML.
D) Doxorubicin is an anthracycline that can cause secondary leukemias, but etoposide has a stronger association with AML development.
Educationally, this question highlights the importance of understanding the long-term effects of chemotherapy in pediatric oncology patients. Healthcare providers need to be aware of the potential risks associated with different chemotherapeutic agents to provide comprehensive care and long-term surveillance for these vulnerable patients.